BTC iShares Core High Dividend ETF
Merck’s Stock Price Has Increased ~34% in 2018
On November 16, Merck’s stock price closed at $76.06, which represents ~1.63% growth from its close of $74.84 on November 15.
How Wall Street Analysts View Merck
On October 25, Merck (MRK) announced a dividend of $0.55 per share for its outstanding common stock in the fourth quarter of 2018.
What’s Pfizer’s Current Valuation?
Pfizer is trading at a forward PE ratio of ~14.5x on October 18—compared to the industry average of ~15.7x.
What’s Expected for Merck’s Q3 2018 Earnings
Analysts expect Merck (MRK) to report GAAP net income of $2.23 billion and GAAP EPS of $0.83 in the third quarter of 2018.
Pfizer’s Dividend Growth Trend and Analysts’ Recommendations
Wall Street analysts expect Pfizer’s (PFE) November dividend to be ~$0.33 and for its quarterly dividend for 2019 to be $0.36.
A Look at Elanco, Eli Lilly’s Animal Health Business
Eli Lilly’s Elanco reported a 1% YoY (year-over-year) rise in revenue to $792.1 million in the second quarter.
Eli Lilly’s Stock Performance in September
Eli Lilly stock reported a ~0.6% rise to close at $106.31 on September 26 compared to the previous day’s close.
A Look at Pfizer’s Market Cap and Shareholding Pattern
The total number of Pfizer’s outstanding shares is ~5.862 billion. Of these, its free-floating shares total ~5.859 billion.
A Look at Eli Lilly’s Neuroscience Products in Q2 2018
Eli Lilly and Company’s (LLY) Human Pharmaceutical segment includes neuroscience products such as Cymbalta, Strattera, and Zyprexa.
These Products Saw Falling Sales in Pfizer’s Q2 2018
Pfizer’s (PFE) portfolio also includes a few products that are losing market share due to competition from other products in the market.
Eli Lily Highlights Study Results of Emgality for Migraines
Emgality is presently under review by the US Food and Drug Administration for migraine prevention.
What’s the Dividend Yield of the Consumer Non-Cyclical Sector?
The consumer non-cyclical segment recorded a dividend yield of 3%.
Merck’s Post-1Q18 Valuation
In 1Q18, Merck’s revenue grew 6% YoY (year-over-year) to $10.0 billion from $9.4 billion, and its EPS (earning per share) rose to $1.05 from $0.88.
What’s Johnson & Johnson’s Valuation after 1Q18 Earnings?
The price-to-earnings (or PE) multiple represents what one share can buy an equity investor.
Factors that Could Drive Dominion Energy’s Dividend Growth
Dominion Energy’s (D) present dividend yield of 4.4% is due to its dividend growth and price loss.
Why The Kraft Heinz Company’s Outlook Still Seems Promising
The Kraft Heinz Company’s (KHC) net sales grew 44% in 2016 before falling 1% in 9M17. Every product category drove the growth in 2016, offset by a decline in the infant and nutrition segments.
Xtandi’s Prescription Volumes Continue to Rise in 2017
In this series, we’ll look at Pfizer’s main revenue drivers in 2017, and what could steer its performance in 2018.
How Facebook Compares to Broad Indexes
Facebook (FB) revenues rose 54% and 47% in 2016 and 9M17, respectively.
Merck’s Immunology and Cardiovascular Franchise in 3Q17
In 3Q17, Merck’s Remicade revenues fell ~31% to $214 million compared to $311 million in 3Q16. The fall was driven by lower sales due to generic competition and biosimilars.
Merck & Co.’s Valuation in November 2017
Merck & Co. (MRK) reported EPS of $1.11 on revenues of $10.3 billion in 3Q17, which was a 2% fall compared to EPS of $1.07 on revenues of $10.5 billion in 3Q16.
Analyzing Devon Energy, a Low Dividend Grower
Devon Energy’s (DVN) revenues fell 36.0% and 7.0% in 2015 and 2016, respectively.
A Look at Corning, Another Top Dividend Grower
Corning’s net sales and earnings in 2015 and 2016 Corning’s (GLW) net sales fell 6% in 2015 before rising 3% in 2016. Its North American net sales rose in 2015 before falling slightly in 2016, and its Asia-Pacific, European, and other net sales fell in 2015 and rose in 2016. In 2015, its Optical Communications segment’s net sales […]
These Pfizer Products Lost Market Share in 3Q17
BeneFIX revenues fell 14% to $151 million during 3Q17, driven by a 16% fall in international sales to $87 million.
What Do Analysts Think about Merck?
Wall Street analysts estimate Merck’s (MRK) top line will increase marginally by 0.1% to ~$10,546 million in 3Q17.
A Look at American Airlines’ Dividend Payouts
Only four airlines—Delta Air Lines (DAL), Southwest Airlines (LUV), American Airlines (AAL), and Alaska Air Group (ALK)—pay dividends to investors.
Delta Air Lines Increased Dividend Payout in 3Q17
Delta Air Lines (DAL) increased its dividend payout 50.0% in 3Q17, resulting in ~$0.31 dividend per share. At that rate, DAL has an indicated dividend yield of 2.3%.
How Dividend Yields of DJIA Stocks in Top Tax Bracket Stack Up
This series will discuss some of the Dow Jones Industrial Average (or DJIA) companies in the highest income tax bracket and their corresponding dividend yields.
Assessing Pfizer’s Performance by Business Segment in 2Q17
Pfizer’s Innovative Health segment contributed ~59% of PFE’s total revenues in 2Q17, and analysts expect the contribution to rise to ~60% in 3Q17.
What Led to BlackRock’s Downward Sloping Dividend Yield Curve?
BlackRock posted a 7.0% revenue growth in the first half of 2017, driven by every segment except multi-asset and alternatives, which reported flat growth.
Decoding Helmerich & Payne’s Dividend Yield
What’s driving Helmerich & Payne’s high yield? Contract oil and gas well driller Helmerich & Payne (HP) recorded a sharp drop in its 2016 operating revenue due to declines in its US drilling, offshore, and international segments. Its revenue fell 19% in 2015, compared with 51% in 2016. Its operating income, as a result, ended […]
A Post-2Q17 Update on Pfizer’s Oncology Drugs: Sutent, Xalkori, and Inlyta
In 2Q17, Inlyta generated revenues of ~$88 million, which represents an ~19% decline on a YoY basis and ~4% growth on a quarter-over-quarter basis.
Dividend Yield of Procter & Gamble
Procter & Gamble’s (PG) PE ratio of 25.1x compares to a sector average of 23.3x. The dividend yield of 3.0% compares to a sector average of 3.8%.
Consolidated Edison’s Dividend Trajectory
Consolidated Edison’s (ED) 2016 operating revenues fell 4.0% due to a decline in every segment; namely, electric, gas, steam, and non-utility.
Pfizer’s Corporate and Pipeline Developments in 2Q17
Apart from Pfizer’s (PFE) product developments, let’s take a look at some recent pipeline and corporate developments.
Has Johnson & Johnson Been Able to Increase Dividends?
Johnson & Johnson’s (JNJ) EPS (earnings per share) for the first half of 2017 fell 0.70%, driven by higher selling, marketing, and administrative and R&D expenses.
Pfizer Sees a Significant Opportunity in This for Revenue Growth
In 2016, Pfizer’s (PFE) biosimilar business reported revenues of ~$319 million, compared with $63 million in 2015.
Can Delta Continue to Be the Best Airline Dividend Payer?
Delta Air Lines (DAL) has an indicated dividend yield of 2.0%, the highest among the four airlines that pay dividends.
The Top Dividend-Growing Financial Sector Stocks
Mercury General (MCY) has consistently recorded revenue growth since fiscal 2011, except for a minor decline in fiscal 2015
IBM’s Dividend Growth Curve
For IBM (IBM), 1Q17 marked the 22nd year of annual dividend growth despite being the 20th successive quarter with no revenue growth.
Merck’s Immunology and Cardiovascular Franchise in 1Q17
The combined revenues for Zetia and Vytorin fell 35% to $575 million in 1Q17, compared to $889 million in 1Q16.
Pfizer’s Segment Performance in 1Q17
Pfizer Innovative Health contributed $7.4 billion, or about 58.0% of Pfizer’s total revenues in 1Q17.
Comparing Growth and Value Stock Sectors
The SPDR S&P 500 Growth ETF (SPYG) has generated a YTD return of 13.3% versus 4.3% from the SPDR S&P 500 Value ETF (SPYV).
Understanding Pfizer’s 1Q17 Performance by Geography
Pfizer (PFE) reported a 2% decline in revenues to ~$12.8 billion for 1Q17, as compared to $13.0 billion in 1Q16.
Eli Lilly’s Business Segments’ Performance in 1Q17
Elanco, Eli Lilly’s Animal Health business, reported growth of 2% to $769.4 million during 1Q17.
TOT, SU, E, and PBR: Comparing Their Dividend Yields
Total (TOT), Suncor Energy (SU), ENI (E), and Petrobras (PBR) have provided steady returns to their shareholders in the form of dividends.
Is BP’s Cash Flow Slated for Growth?
Rising oil prices have given BP some hope that its cash flows could improve. The robust upstream project pipeline is also likely to result in higher production.
Who Has Higher Dividend Yields: RDS.A, XOM, CVX, or BP?
Shell has the highest dividend yield of 7.1% among the integrated energy stocks we’re covering in this series.
Performance of Eli Lilly & Co.’s Elanco in 1Q17
Eli Lilly & Co.’s (LLY) Animal Health company, Elanco, reported an increase of 2% in revenues to $769.4 million in 1Q17, compared to $754.6 million in 1Q16.
Eli Lilly’s 1Q17 Estimates for Humalog, Other Endocrine Products
Eli Lilly’s (LLY) human pharmaceutical segment contributes ~85.0% to Lilly’s total revenues.
Inside Integrated Energy’s Dividend Yields: Comparing XOM, CVX, RDS.A, and BP
ExxonMobil (XOM), Chevron (CVX), Royal Dutch Shell (RDS.A), and BP (BP) have consistently given returns to shareholders in the form of dividends.
TOT, SU, E, PBR: Who Has Highest Dividend Yield?
Total (TOT), Suncor Energy (SU), ENI (E), and Petrobras (PBR) have consistently given returns to shareholders in the form of dividends.
Integrated Energy Stocks: Who Stands Tall in Dividend Yield?
Shell’s dividend yield is 7.1%, the highest among the integrated energy stocks in this series.
What Wall Street Analysts Are Saying about Eli Lilly
Eli Lilly (LLY) reported EPS (earnings per share) of $2.58 on revenue of $21.2 billion in 2016, compared to EPS of $2.26 on revenue of $20.0 million in 2015.
How Chevron’s Dividend Yield Has Trended
Chevron’s dividend yield Chevron (CVX) has consistently given returns to shareholders in the form of dividends. Therefore, we have evaluated its dividend yields. Yield is calculated as a ratio of the annualized dividend to stock price. Chevron’s dividend yield rose from 3.3% in 4Q13 to 4.1% in 4Q16, due to a dividend increase coupled with […]
Johnson & Johnson’s Consumer Segment
Johnson & Johnson’s (JNJ) Consumer segment revenues fell 1.5% to ~$13.3 billion for 2016, compared to 2015.
Inside ExxonMobil’s Dividend Yield
ExxonMobil’s dividend yield rose from 2.8% in 4Q13 to 3.6% in 4Q16.
Understanding Pfizer’s Growth Contributors in 4Q16
The key performers in Pfizer’s (PFE) product portfolio include Lyrica, Ibrance, Xeljanz, and Eliquis, which are in the company’s Innovative Health business.
Januvia and Janumet: Merck & Co.’s Blockbuster Diabetes Products
Januvia and Janumet together contributed about 14.9% of Merck & Co.’s total revenues for 4Q16, an ~0.7% increase compared to 4Q15
XOM, CVX, RDS.A, BP: Who Has Better Dividend Yields?
ExxonMobil (XOM), Chevron (CVX), Royal Dutch Shell (RDS.A), and BP (BP) have consistently given returns to shareholders in the form of dividends.
Johnson & Johnson’s Consumer Segment’s 4Q16 Earnings
Johnson & Johnson’s (JNJ) Consumer segment’s revenue rose 3.4% to $3.4 billion in 4Q16 compared to 4Q15. This rise included an operational rise of 4.9%.
What Does a Cash Flow Analysis of Valero Energy Reveal?
Valero saw a rise in its cash balance in the first nine months of 2016. VLO’s cash balance in the period stood at $5.9 billion, showing a 12% rise over the first nine months of 2015.
Which Assets Find Support in a Reflationary Environment?
The focus can now shift to the assets that are more cyclical, like financials (XLF) (IYF), utilities (XLU) (IGF), and dividend growers.
Merck Is Getting Serious about Animal Health
Merck’s (MRK) Animal Health segment operates in more than 140 countries worldwide. The global sales reported for 3Q16 totaled ~$865 million.
Are Dividend Growers a Better Option Than Dividend Payers?
With a gradual increase in interest rates, dividend-growing companies have room to grow and can offer a higher yield with higher income. On the other hand, dividend-paying companies have no room for growth.
Pfizer’s Xeljanz Expected to See Strong Growth Trends in 2016
Pfizer’s (PFE) inflammation and immunology drug Xeljanz has seen strong growth trends in 2016, mainly due to high efficacy as a monotherapy and increasing brand awareness.
Pfizer Aims to Position Avelumab as Backbone Immuno-Oncology Therapy
On June 6, Pfizer and Merck announced positive results from a Phase 2 study testing Avelumab as a therapy for previously treated Merkel cell carcinoma.
What Do Analysts Say about JNJ after Its 3Q16 Results?
Based on recommendations from 25 broker firms in a Bloomberg survey, Johnson & Johnson (JNJ) received “buy” ratings from ~44% of the firms, and ~56% of the firms rated the company a “hold.” None of the firms gave a “sell” rating to Johnson & Johnson.
Are Earnings Expectations for ExxonMobil Improving?
ExxonMobil (XOM) is expected to post its 3Q16 results on October 28, 2016. In 2Q16, XOM’s revenues surpassed Wall Street estimates by 5%.
Could Johnson & Johnson’s Earnings Grow in 3Q16?
Analysts’ estimates Johnson & Johnson (JNJ) accounts for ~6.3% of the total holdings of the iShares Core High Dividend ETF (HDV). The company has managed to exceed analysts’ earnings estimates for the last several quarters. The movement in a company’s share price is generally impacted by the deviation of its actual results from analysts’ estimates. Usually, a stock’s […]
What’s the Outlook for Pfizer?
Analysts estimates The strong performance Pfizer’s (PFE) innovative products and the inclusion of the Hospira business have driven the company’s 2Q16 earnings, surpassing analysts’ estimates for revenues and EPS (earnings per share). Pfizer reported EPS of $0.64 on revenues of $13.2 billion in 2Q16, against the estimated EPS of $0.62 on revenues of $13.0 billion. Due […]
How Pfizer’s Internal Medicine Core Drugs Are Performing
The major contributors in Pfizer’s (PFE) Internal Medicine business include Lyrica and Viagra. Lyrica’s Innovative Health (or IH) contribution to the Internal Medicine portfolio stood at 48%.
How Johnson & Johnson’s Partnerships Enhance Customer Value
Johnson & Johnson’s key innovation strategies include creating value through strategic customer partnerships and solutions.
Do Dividend Growers Look Appealing?
Historically, dividend growers have often performed better than the S&P 500 (IVV) and provided higher income during Market volatility.
Why Is Pfizer’s Valuation Low Compared to Its Peers?
On August 8, 2016, Pfizer (PFE) was trading at a forward PE multiple of ~13.8x. The industry currently trades at a forward PE multiple of ~17.2x.
How Did BP’s 2Q16 Earnings Stand up to Analyst Estimates?
BP reported its 2Q16 earnings on July 26. Its revenues missed analyst estimates by 4%. It reported a loss of $0.46 in EPS, but adjusted EPS stood at $0.23.
Petrobras’s Institutional Holdings, Pre-2Q16 Results
Petrobras’s (PBR) institutional holdings currently stand at ~12%.
Where Do HFC’s Institutional Holdings Stand Pre-Earnings?
HollyFrontier’s (HFC) institutional holdings currently stand at ~98%.
ExxonMobil’s 2Q Earnings Expected to Outshine 1Q Results
According to Wall Street analysts’ estimates, ExxonMobil is expected to post earnings per share of $0.64 in 2Q16—36% lower than 2Q15’s adjusted EPS.
What to Expect from Suncor Energy’s Business Segments in 2Q16
Suncor Energy’s (SU) Refining and Marketing segment’s operating earnings fell by 52% from 1Q15 to 241 million Canadian dollars in 1Q16.
Analyzing Tobacco Companies’ 1Q16 Inventory Levels
1Q16 inventory levels were lower for tobacco companies due to falling cigarette shipment volumes.
Analyzing Dominion Resources’ Forward Dividend Yield
As of June 28, 2016, Dominion Resources is trading at a forward dividend yield of 3.7%. The three-year historical average for its forward dividend yield is 4%.
Why Are BP’s Cash Reserves Plunging?
In 1Q16, BP’s cash flow from operations stood at $1.9 billion, almost the same as in 1Q15. Its cash outflow from investing stood at $3.2 billion in 1Q16.
What Does Tesoro’s Refining Index Tell Us?
In 2Q16 to date, Tesoro’s refining index values have risen compared to 1Q16 but have fallen compared to 2Q15. These values are regional crack indicators in the areas where TSO operates.
Philip Morris’s 1Q16 Shipment Volume Declined in Russia
PM’s increase in revenue on a constant currency basis was primarily due to favorable pricing of $0.1 billion, driven by Russia and Turkey, and partially offset by Ukraine.
What Are the Roles of Debt and Dividends in Eni’s Cash Flow?
In 2015, Eni’s (E) cash flow from operations stood at 12 billion euros, falling from 15 billion euros in 2014.
Why Did Beauty Companies’ Operating Margins Shrink in 4Q15?
Beauty companies have been investing heavily in growth initiatives, which is impacting their margins.
How Can Tobacco Companies Improve 1Q16 Inventory Levels?
Inventory levels for 4Q15 were lower for tobacco companies due to declining shipment volume of cigarettes. The overall cigarette industry volume declined 0.5% in 4Q15.
PM Is Increasing Prices in Russia due to the Weakening Ruble
PM’s rise in revenue in Eastern Europe, the Middle East, and Africa was primarily due to favorable pricing driven by Russia, Turkey, and the Ukraine.
Chevron Closes Slightly Higher following Its 4Q15 Results
Chevron announced its 4Q15 results on January 29, before the market opened. As Chevron missed its estimates for 4Q15, the stock received a weak opening.
AT&T Boosted Its Mid-Band Spectrum Portfolio in 2015
AT&T completed a ~$18.2 billion transaction of AWS-3 spectrum holdings during 1Q15. It bought these spectrum holdings at the FCC’s AWS-3 spectrum auction.
Verizon’s Wireless Promotional Efforts
Verizon’s Marni Walden discussed how the move from traditional subsidy models to installment plans may be affecting the company’s promotional efforts.
Consumer Packaged Goods Companies Saw Improved Margins
CPG companies’ 3Q15 margins sent strong signals. They have been investing in innovative products and other growth initiatives. This is impacting their margins.
Analyzing the Potential Growth of Verizon’s Installment Plans
Sequentially, the take rate of Verizon’s installment plans has been increasing evenly.
Analyzing Verizon’s Value Proposition in the US Telecom Space
Verizon’s average five-year dividend yield is ~4.7%, which is slightly lower than AT&T’s dividend yield of ~5.4%.
What’s Happening with Verizon’s Wireline Asset Sale to Frontier?
In this series, we will look at some key points that Verizon (VZ) discussed at the recent UBS Global Media and Communications Conference on December 7, 2015.
What Are the Key Factors that Drive Upstream Costs?
With crude oil prices declining in 2014, integrated energy companies have lowered their E&P capital expenditures.
What Led Cliffs to Increase Its Realized Revenues for US Iron Ore?
Cliffs Natural Resources’ (CLF) realized revenues from USIO (or US iron ore division) were lower than expected.
Is the Market Underestimating Nucor’s Earnings Capacity?
In this series, we’ll analyze Nucor’s 3Q15 earnings and explore the factors that drove its financial performance amid challenging steel market conditions.
Why Philip Morris’s EEMA Region Saw Revenue Wobbles in 3Q15
Philip Morris’s 3Q15 revenues from the EEMA region decreased by 13.8% to $2.1 billion due to an unfavorable currency impact of $0.6 billion.
How Did Intel’s Business Segments Perform?
Intel operates through four major business segments—Client Computing Group, Data Center Group, Internet of Things Group, and Software and Services Group.